Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Auto-HSCT for Newly Diagnosed DLBCL
NCT07680933Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by The Affiliated Hospital of Xuzhou Medical University. Started Mar 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07680933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680933.